Zacks Company Profile for Penumbra, Inc. (PEN : NYSE) |
|
|
|
Company Description |
Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California.
Number of Employees: 4,500 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $251.06 |
Daily Weekly Monthly
 |
20 Day Moving Average: 402,092 shares |
Shares Outstanding: 38.73 (millions) |
Market Capitalization: $9,722.55 (millions) |
Beta: 0.47 |
52 Week High: $310.00 |
52 Week Low: $148.00 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
-2.83% |
-8.10% |
12 Week |
-6.52% |
-21.58% |
Year To Date |
5.72% |
-0.98% |
|
|
|
|
|
|
|
General Corporate Information |
Officers
Adam Elsesser - Chief Executive Officer; Chairman and President
Maggie Yuen - Chief Financial Officer
Lambert Shiu - Chief Accounting Officer
Don Kassing - Director
Harpreet Grewal - Director
|
|
Peer Information
Penumbra, Inc. (ABMD)
Penumbra, Inc. (DMDS)
Penumbra, Inc. (CPWY.)
Penumbra, Inc. (EQUR)
Penumbra, Inc. (ECIA)
Penumbra, Inc. (FMS)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 70975L107
SIC: 3841
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/29/25
|
|
Share - Related Items
Shares Outstanding: 38.73
Most Recent Split Date: (:1)
Beta: 0.47
Market Capitalization: $9,722.55 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $0.96 |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $3.72 |
Payout Ratio: 0.00 |
Number of Estimates in the Fiscal Year Consensus: 10.00 |
Change In Payout Ratio: 0.00 |
Estmated Long-Term EPS Growth Rate: 30.18% |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 07/29/25 |
|
|
|
|